GlassScriptPhysician profile
Emiley Neudorfer
NPI 1699253062
$5,387.18
in general payments reported to CMS, 2019-2025
33 companies · $1,376 in 2025
The $1,376 reported for 2025 was more than what 91% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $802 · 2022: $953 · 2023: $1,201 · 2024: $1,056 · 2025: $1,376.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,501 · Education: $132.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,500.75 |
| Education | $131.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $918.73 | 2021-2025 | |
| Novo Nordisk INC | $734.82 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $607.78 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Glaxosmithkline, LLC. | $446.33 | 2021-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Teva Pharmaceuticals USA, INC. | $327.37 | 2021-2025 | Austedo Xr, Ajovy, Austedo Xr |
| Novartis Pharmaceuticals Corporation | $229.94 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $206.24 | 2021-2025 | Airsupra, Farxiga, Breztri |
| Pfizer INC. | $178.99 | 2021-2025 | |
| Amgen INC. | $160.77 | 2021-2025 | Repatha, Otezla, Repatha |
| Abbott Laboratories | $159.39 | 2021-2025 | Freestyle Libre 3, Proclaim, Freestyle Libre 2 |
| Janssen Pharmaceuticals, INC | $147.06 | 2021-2024 | Xarelto |
| Kowa Pharmaceuticals America, INC. | $124.70 | 2022-2025 | Livalo, Zoryve, Seglentis |
| Daiichi Sankyo INC. | $118.08 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $116.47 | 2021-2024 | Jardiance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $112.90 | 2023-2025 | Xifaxan, Trulance |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $104.81 | 2024-2025 | Voquezna |
| Shield Therapeutics INC | $83.85 | 2023-2024 | Accrufer |
| Merck Sharp & Dohme LLC | $82.57 | 2021-2023 | Verquvo, Belsomra |
| Astellas Pharma US INC | $72.96 | 2022-2025 | Veozah |
| Biohaven Pharmaceutical Holding Company LTD. | $71.82 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $69.13 | 2022-2025 | |
| Exact Sciences Corporation | $65.58 | 2024-2025 | Cologuard Collection Kit |
| E.R. Squibb & Sons, L.L.C. | $43.72 | 2021-2024 | Camzyos |
| Boston Scientific Corporation | $38.22 | 2023 | Watchman Flx |
| Biohaven Pharmaceuticals, INC. | $30.02 | 2021 | |
| Sanofi-Aventis U.S. LLC | $29.96 | 2022-2023 | |
| Dexcom, INC. | $18.54 | 2022 | |
| Edwards Lifesciences Corporation | $16.45 | 2023 | |
| Paratek Pharmaceuticals, INC. | $15.86 | 2024 | Nuzyra |
| Otsuka America Pharmaceutical, INC. | $14.91 | 2022 | |
| Supernus Pharmaceuticals, INC. | $14.42 | 2021 | |
| Arbor Pharmaceuticals, INC. | $12.40 | 2021 | |
| Almatica Pharma LLC | $12.39 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Emiley Neudorfer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.